JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
IgG-defined Hypogammaglobulinemia at Diagnosis and Survival Outcomes in Diffuse Large B-Cell Lymphoma
Abstract
Aims: To evaluate the prognostic value of hypogammaglobulinemia at diagnosis in patients with diffuse large B-cell lymphoma (DLBCL) and its association with clinical characteristics and survival outcomes.
Methods: A total of 177 adult patients with newly diagnosed DLBCL and available serum immunoglobulin G (IgG) levels were retrospectively analyzed. IgG-defined hypogammaglobulinemia was defined as IgG <700 mg/dL at diagnosis.
Results: IgG-defined hypogammaglobulinemia was identified in 27 patients (15.3%). There were no significant differences between patients with and without IgG-defined hypogammaglobulinemia in terms of age and sex distribution. However, IgG-defined hypogammaglobulinemia was associated with more frequent B symptoms, extranodal involvement, elevated lactate dehydrogenase levels, poor Revised International Prognostic Index (R-IPI) scores, lower serum albumin levels, and a higher rate of infections during follow-up. The median follow-up time was 33 months (range, 0,1-166 months). Patients with IgG-defined hypogammaglobulinemia had significantly shorter progression-free survival (PFS) (p=0.044) and overall survival (OS) (p=0.001). In univariable analysis, IgG-defined hypogammaglobulinemia, ECOG performance status >1, poor R-IPI score, low albumin levels, presence of B symptoms, bone marrow involvement, and infection during follow-up were associated with inferior survival outcomes. In multivariable analysis, IgG-defined hypogammaglobulinemia was not an independent prognostic factor for PFS but remained independently associated with OS in the model including R-IPI.
Conclusion: IgG-defined hypogammaglobulinemia at diagnosis may be associated with inferior survival outcomes in patients with DLBCL. Further prospective multicenter studies are needed to clarify its independent prognostic significance and potential role in risk stratification.

Keywords : Diffuse large B-cell lymphoma, hypogammaglobulinemia, immunoglobulin G, prognosis, survival

Download Article


1. Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016; 101(10):1244-1250. doi:10.3324/haematol.2016.148809
2. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987-994. doi:10.1056/NEJM199309303291402
3. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861. doi:10.1182/blood-2006-08-038257
4. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842. doi:10.1182/blood-2013-09-524108
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511. doi:10.1038/35000501
6. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947. doi:10.1056/NEJMoa012914
7. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1): 275-282. doi:10.1182/blood-2003-05-1545
8. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331. doi:10.1182/blood-2010-09-297879
9. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-2390. doi:10.1182/blood-2016-01-643569
10. Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504-514. doi:10.1111/bjh.13463
11. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87. doi:10.1016/j.pathol.2017.09.006
12. Han Y, Yang J, Liu P, He X, Wang L, Zhang C. Prognostic nomogram for overall survival in patients with diffuse large B-cell lymphoma. Oncologist. 2019;24(11):e1251-e1261. doi:10.1634/theoncologist.2018-0361
13. Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121(17):2883-2891. doi:10.1002/cncr.29438
14. Andersen MA, Vojdeman FJ, Andersen MK, Brown P, Geisler CH, Frederiksen H. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016;57(7):1592-1599. doi:10.3109/10428194.2016.1142082
15. Svensson T, Höglund M, Cherif H. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. Scand J Infect Dis. 2013;45(7):537-542. doi:10. 3109/00365548.2013.769279
16. Brazel D, Grant C, Cabal A, et al. Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis. Front Immunol. 2024;15:1334899. doi:10.3389/fimmu.2024.1334899
17. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106-111. doi:10.1016/j.clml.2012.11.011
18. Filanovsky K, Miller EB, Sigler E, et al. Incidence of profound hypogammaglobulinemia and infection rate in lymphoma patients following the combination of chemotherapy and rituximab. Recent Pat Anticancer Drug Discov. 2016;11(2):228-235. doi:10.2174/1574892811666160129110614
19. Singh N, Mott SL, McCarthy AN, et al. Prevalence and the impact of hypogammaglobulinemia in newly diagnosed, untreated diffuse large B-cell lymphoma. Blood. 2019;134:1604.
20. Pan BH, Kong YL, Wang L, et al. The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;62(2): 291-299. doi:10.1080/10428194.2020.1832673
21. Lindberg A, Johansson A, Kahn F, et al. Hypogammaglobulinemia at diagnosis is associated with inferior survival and higher risk of infections in diffuse large B cell lymphoma. Hematol Oncol. 2025;43(1): e70014. doi:10.1002/hon.70014
22. Ben-Bassat I, Many A, Modan M, Peretz H, Ramot B. Serum immunoglobulins in chronic lymphocytic leukemia. Am J Med Sci. 1979;61(2):279-283. doi:10.1097/00000441-197907000-00001
23. Itala M, Helenius H, Nikoskelainen J, Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol. 1992;48(5):266-270. doi:10.1111/j.1600-0609.1992.tb01805.x
24. Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(1):99-104. doi:10.3109/10428194.2012.706285
25. Molica S, Levato D, Levato L. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica. 1993;78(6):374-377.
26. Baek DW, Song GY, Lee HS, et al. Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era. Front Oncol. 2024;14:1380492. doi:10.3389/fonc.2024.1380492
Article available in :
Volume 4, Issue 3, 2026
Page : 93-98
https://doi.org/10.51271/JCHOR-0089
Article Information
Received : 30 Mar 2026
Accepted : 22 Haz 2026
Published : 08 Ağu 2026
Corresponding Author :

Ozan Salim: Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Akdeniz University, Antalya, Turkiye

[email protected]
Citation : Öztekin S, Ataş Ü, Iltar U, Yücel OK, Salim O, Ündar L. IgG-defined hypogammaglobulinemia at diagnosis and survival outcomes in diffuse large B-cell lymphoma. J Curr Hematol Oncol Res. 2026;4(3):93-98. doi:10.51271/JCHOR-0089

Read: 11
Download : 4
Cited: 0
_Footer